Introduction
============

Colorectal cancer (CRC) is a worldwide health burden, ranking the third most common cancer in men and the second in women.[@b1-ott-10-3591] Despite progress made in the treatment of CRC, which has increased survival rates of CRC patients, metastasis, recurrence, and chemoresistance remain as obstacles to effective therapy.[@b2-ott-10-3591]--[@b4-ott-10-3591] Therefore, discovering innovative therapeutic agents are urgently required to combat these problems.

The ubiquitin--proteasome system (UPS) is the major proteolytic system mediating the degradation of intracellular proteins in eukaryotes.[@b5-ott-10-3591] Misfolded, damaged, or specific proteins are targeted for destruction through the attachment of ubiquitin molecules and degraded by the 26S proteasome.[@b6-ott-10-3591]--[@b8-ott-10-3591] These proteasome substrates include regulatory proteins involved in cell proliferation, cell cycle regulation, transcription, signal transduction, apoptosis, and many other biological processes (BPs).[@b9-ott-10-3591],[@b10-ott-10-3591] The stabilization of UPS is necessary for maintaining cellular homeostasis and normal functions.

Malignant cells, with hypermetabolism and uncontrolled proliferation, depend more on high proteasome activity than normal cells. Inhibition of proteasome activity may cause various effects on tumor cells, including anti-inflammatory, antiproliferative, and apoptotic effects, which result in cancer cell death ultimately. It has been reported that malignant cells are highly susceptible to proteasome inhibition.[@b11-ott-10-3591]--[@b13-ott-10-3591] Therefore, proteasome inhibitors emerged as attractive anticancer therapeutics.

Ixazomib (MLN2238), a novel proteasome inhibitor, was approved by US Food and Drug Administration in November 2015 for use in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who received at least one previous therapy.[@b14-ott-10-3591] It is the first globally approved, orally administered proteasome inhibitor used for the treatment of this patient population.[@b15-ott-10-3591] It not only achieved satisfactory clinical outcomes in MM patients but also showed obvious anticancer effects against multiple tumors including chronic lymphocytic leukemia, prostate cancer, breast cancer, and neuroblastoma.[@b16-ott-10-3591]--[@b19-ott-10-3591] However, researches focusing on the antitumor effects of ixazomib on CRC are limited, and the anti-CRC mechanisms of ixazomib remain far more to be elucidated.

In this study, we utilized a microarray- and bioinformatics-based method to identify the anticancer effects of ixazomib on CRC cells. Differentially expressed genes (DEGs) were screened out between SW620 cells treated with or without ixazomib. Functional and pathway enrichment analyses were performed for the DEGs to recognize the biological functions and signaling pathways affected by ixazomib. Protein--protein interaction (PPI) network was constructed to identify hub genes. Subnetwork analysis was further performed to mine the molecular complex in the PPI network. To the best of our knowledge, this is the first study using a combined method of microarray and bioinformatics analysis to identify the comprehensive anticancer mechanisms of ixazomib on CRC cells. Our study demonstrated ixazomib as a potential drug against CRC, providing new insights on CRC therapy.

Materials and methods
=====================

Cell culture
------------

Human CRC cell line SW620 was obtained from the Cell Bank of the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). The cells were cultured in RPMI-1640 medium (HyClone Laboratories, Logan, UT, USA) supplemented with 10% fetal bovine serum (Clark Bioscience, Seabrook, MD, USA), 100 U/mL penicillin, and 100 μg/mL streptomycin (Beyotime Institute of Biotechnology, Shanghai, China) at 37°C in a humidified atmosphere containing 5% CO~2~.

CCK-8 test for cell proliferation assay
---------------------------------------

Cell proliferation was measured by CCK-8 assay (Dojindo Molecular Technologies, Inc., Rockville, MD, USA) according to the manufacturer's instructions. SW620 cells (2×10^4^/mL) suspended in RPMI-1640 medium containing 10% fetal bovine serum were seeded in 96-well plates with 100 μL/well and incubated for 24 h. The cells were then treated with various concentrations of ixazomib (Selleck, Shanghai, China) for 24 and 48 h. Cells incubated without ixazomib for the same periods of time were set as the control groups. After various periods of incubation, 10 μL of CCK-8 solution was added to each well and incubated with cells for 2 h at 37°C. The optical density was then detected with a microplate reader at a wavelength of 450 nm.

Cancer cells' treatment, RNA extraction, and purification
---------------------------------------------------------

SW620 cells were seeded in a sterile cell culture dish (10×10 cm) for 24 h first to allow for cell attachment and growth. Then, cells were treated with ixazomib at the concentration of 1 μmol/L (1,000 nmol/L), which exerts a moderate inhibition on the proliferation of SW620 cells according to the CCK-8 cell proliferation assay, for 24 h. Cells cultured without ixazomib for the same culture time were set as the controls. Following 24 h incubation at 37°C, the cells were harvested and the total RNA was extracted using the TRIzol reagent (Thermo Fisher Scientific, Waltham, MA, USA). RNA quantity and quality were assessed using the Nanodrop and Agilent 2100 bioanalyzer systems, respectively. The experiment was carried out in triplicate. Then, the qualified RNAs from three samples treated with ixazomib and three control (untreated) samples were further purified using the NucleoSpin^®^ RNA Clean-up XS kit (Macherey-Nagel, Düren, Germany) and RNase-Free DNase Set (Qiagen NV, Venlo, the Netherlands) according to the manufacturers' instructions.

Microarray hybridization procedure
----------------------------------

Gene expression levels of each sample were measured using the Affymetrix GeneChip Human Genome U133 Plus 2.0 Array (Affymetrix, Inc., Santa Clara, CA, USA). According to the manufacturer's instructions, total RNA were amplified, labeled using the GeneChip™ 3′ IVT PLUS Reagent Kit (Affymetrix, Inc.) to obtain biotin-labeled cRNA. Microarray hybridization and washing were carried out using the GeneChip™ Hybridization, Wash, and Stain Kit (Affymetrix, Inc.) in Hybridization Oven 645 (Affymetrix, Inc.) and Fluidics Station 450 (Affymetrix, Inc.). Slides were scanned by GeneChip^®^ Scanner 3000 (Affymetrix, Inc.) and Command Console Software 4.0 (Affymetrix, Inc.) with default settings. Then, a total of six CEL files (three files of ixazomib-treated samples and three control samples) were obtained for further analysis.

Microarray data preprocessing
-----------------------------

The raw data in CEL files of the six samples were first converted into probe expression values using the affy package in R language and preprocessed for background adjustment, quantile normalization, final summarization, and log~2~ transformation by robust multiarray average (RMA) algorithm in affy package.[@b20-ott-10-3591],[@b21-ott-10-3591] Then, the probe-level data were transformed to the expression values of genes according to the probe set annotation file of Affymetrix GeneChip Human Genome U133 Plus 2.0 Array, which was downloaded from the website of Affymetrix. If more than one probe corresponded to the same gene symbol, the average expression value of these probes was calculated as the expression value of the specific gene. After data preprocessing, we got the expression profile dataset including 21,275 genes for each of the six samples.

DEGs screening and hierarchical clustering analysis
---------------------------------------------------

The DEGs between ixazomib-treated samples and control samples were identified using the Linear Models for Microarray data (LIMMA) package in R language.[@b22-ott-10-3591] The log~2~fold change (log~2~FC) was calculated. And, the \|log~2~FC\| \>1.5 and adjusted *P*-value \<0.05 were used as the threshold for identifying DEGs. Hierarchical clustering analysis of the identified DEGs was further performed using the pheatmap package in R and displayed in a heatmap.[@b23-ott-10-3591]

Gene Ontology (GO) functional and KEGG pathway enrichment analysis of DEGs
--------------------------------------------------------------------------

The GO analysis is a commonly used approach providing functional studies of large-scale genomic or transcriptomic data.[@b24-ott-10-3591] Kyoto Encyclopedia of Genes and Genomes (KEGG) database collects the pathway-related information about how molecules are networked.[@b25-ott-10-3591] In the present study, the GO functional analysis comprising three ontology categories of BP, cellular component (CC), and molecular function (MF) for the DEGs was performed using the Database for Annotation, Visualization and Integrated Discovery (DAVID, Version 6.8; <https://david.ncifcrf.gov/>), an online tool containing an integrated biological knowledgebase and analytic tools for systematically extracting biological meaning from a large number of genes or proteins.[@b26-ott-10-3591] The *P*-value \<0.05 was set as the cutoff criterion for GO functional analysis. The KEGG enrichment analysis was carried out by KEGG Orthology-Based Annotation System (KOBAS; <http://kobas.cbi.pku.edu.cn/>) to identify the most significantly enriched KEGG pathways of the DEGs with corrected *P*-value \<0.05 set as the threshold.[@b27-ott-10-3591]

Construction of PPI network
---------------------------

The PPI network of DEGs was constructed using the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING, Version 10.0; <http://www.string-db.org/>), which contains information regarding \>932 million interactions of \>9 million proteins.[@b28-ott-10-3591] Interactions including stable physical associations, transient binding, substrate chaining, and information relay between the DEGs were considered for PPI network construction. All interactions in the PPI network were provided with a confidence score, which represented the existence possibility of the interaction judged by STRING between the two genes. Only interactions with the score of ≥0.4 were selected for PPI network construction, and the PPI network was visualized using the Cytoscape (<http://cytoscape.org/>) software.[@b29-ott-10-3591] Genes serve as "nodes" in the PPI network, and edges stand for associated interactions. The "degree" of a node represents the number of interactions between the specific gene and other genes. In the study, the connectivity degree of each network node was calculated by the plugin of CentiScaPe (<http://apps.cytoscape.org/apps/centiscape>) in Cytoscape.[@b30-ott-10-3591] Nodes with a degree of more than 10 were deemed as hub nodes, indicating close connections with other nodes and crucial roles in the network.

Module mining and analysis of the PPI network
---------------------------------------------

Genes in the same network module often execute the same BPs together. In this study, the plugin of Molecular Complex Detection (MCODE) in Cytoscape was used to mine and analyze modules from original PPI network.[@b31-ott-10-3591] The significant modules with MCODE score ≥5 and nodes ≥5 were further selected for GO BP analysis to find important BPs where these modules participated in, which was performed using the DAVID online tool with a threshold of *P*-value \<0.05.

Results
=======

Ixazomib inhibits the proliferation of SW620 cells in a dose-dependent and time-dependent manner
------------------------------------------------------------------------------------------------

The effect of ixazomib on the proliferation of CRC SW620 cells was determined by the CCK-8 assay. For ixazomib at the concentration of 100, 500, 1,000, and 2,000 nmol/L with a treatment time of 24 h, the inhibition rate (mean ± standard deviation) was 4.69±8.04, 28.36±4.49, 35.03±3.49, and 39.46%±2.58%, respectively, compared with the control groups. The corresponding inhibition rate with the same ixazomib concentration gradient for a treatment time of 48 h was 13.60±8.74, 41.88±3.34, 59.29±12.70, and 84.07%±2.67%, respectively. As shown in [Figure 1](#f1-ott-10-3591){ref-type="fig"}, the inhibition rate gradually increased with an increase in concentration and treatment time of ixazomib, indicating that ixazomib inhibits the proliferation of SW620 cells in a dose-dependent and time-dependent manner.

Identification of DEGs between ixazomib-treated and untreated samples
---------------------------------------------------------------------

To remove systematic bias, the original data were first preprocessed by affy package in R language. Gene expression profile data with an excellent degree of standardization were used for the analysis of DEGs. Based on the cutoff criteria, a total of 743 DEGs were identified between ixazomib-treated and untreated samples, including 203 upregulated and 540 downregulated genes. The genes' expression variations are shown in volcano plot in [Figure 2](#f2-ott-10-3591){ref-type="fig"}, with DEGs marked in red. The top 10 significantly upregulated and downregulated DEGs are listed in [Table 1](#t1-ott-10-3591){ref-type="table"}.

Hierarchical clustering of DEGs
-------------------------------

Hierarchical clustering of the identified DEGs is displayed in [Figure 3](#f3-ott-10-3591){ref-type="fig"}. As shown in the heatmap, three ixazomib-treated samples owned strong gene expression similarity and were categorized into one cluster, whereas three untreated samples were grouped into the other cluster. The results of hierarchical cluster analysis demonstrated that based on the expression of DEGs, the ixazomib-treated samples could be clearly distinguished from the untreated samples, which indicated good specificity of the DEGs.

GO functional enrichment analysis
---------------------------------

Based on the cutoff criterion, a total of 83 GO terms were enriched by the DEGs, including 67 BP terms, eight CC terms, and eight MF terms. According to the BP terms, DEGs mainly participated in BPs regarding responses to unfolded protein and protein refolding (GO:0006986, GO:0036499, and GO:0042026), apoptosis (GO:0042981, GO:0043065, GO:0006915, and GO:0097193), negative regulation of cell proliferation and growth (GO:0008285 and GO:0030308), and cell cycle arrest (GO:0006977 and GO:0007050). According to the CC terms, DEGs were principally enriched in mitochondrion-related CCs (GO:0005739 and GO:0005759) and proteasome-related CCs (GO:0000502 and GO:0022624). According to the MF terms, DEGs were enriched in MFs including protein binding (GO:0005515 and GO:0051082), transcription factor activity (GO:0000982), hydrolase activity (GO:0016787), and phosphatase activity (GO:0016791). The top 35 BP terms and all the eight CC terms and MF terms are listed in [Table 2](#t2-ott-10-3591){ref-type="table"}, and the rest 32 BP terms are listed in [Table S1](#SD1-ott-10-3591){ref-type="supplementary-material"}.

KEGG pathway enrichment analysis
--------------------------------

There were 37 KEGG pathways enriched in the study, including metabolic pathways (hsa01100), apoptosis (hsa04210), cell cycle (hsa04110), p53 signaling pathway (hsa04115), and MAPK signaling pathway (hsa04010). The top 25 significantly enriched KEGG pathways of DEGs are listed in [Table 3](#t3-ott-10-3591){ref-type="table"}, and the KEGG pathway of apoptosis is displayed in [Figure 4](#f4-ott-10-3591){ref-type="fig"}, with DEGs colored in red. Notably, the pathway of proteasome (hsa03050), which was directly related to the mechanism of ixazomib, was enriched in KEGG analysis, demonstrating the credibility of the results.

PPI network construction and hub gene identification
----------------------------------------------------

After STRING analysis of the DEGs, the PPI network was constructed with 430 nodes and 1,126 interactions and is shown in [Figure 5](#f5-ott-10-3591){ref-type="fig"}. After degree calculating, a total of 46 hub genes were identified with the degree of \>10 ([Table 4](#t4-ott-10-3591){ref-type="table"}). Among these, *TP53*, *TSPO*, *JUN*, *FOS*, *ITGA2*, *CDKN1A*, *DECR1*, *HSPA5*, *BMP4*, and *HMOX1* were the top 10 hub genes with the closest connections to other nodes.

Module analysis of the PPI network
----------------------------------

A total of 17 modules were mined from the PPI network. Among these, three modules (Module 1, Module 2, and Module 3) with both MCODE score ≥5 and nodes ≥5 ([Figure 6](#f6-ott-10-3591){ref-type="fig"}) were further selected for functional analysis. GO BP functional analysis showed that the functions of Module 1 were mainly associated with transcription (GO:0006366, GO:0045944, GO:1902895, and GO:0061614), the regulation of apoptosis (GO:0043065 and GO:0042981), and the regulation of cell proliferation (GO:0008285 and GO:0042127) ([Table S2](#SD2-ott-10-3591){ref-type="supplementary-material"}). Module 2 exhibited a close relationship with BPs about cell cycle arrest (GO:0071850 and GO:0007050) and cellular response to stimuli (GO:0034198 and GO:0006979) ([Table S3](#SD3-ott-10-3591){ref-type="supplementary-material"}). The genes in Module 3 were mainly associated with ubiquitin-dependent protein catabolism (GO:0051436 and GO:0043161) and cellular signaling pathway (such as GO:0090090, GO:0038061, and GO:0060071) ([Table S4](#SD4-ott-10-3591){ref-type="supplementary-material"}).

Discussion
==========

CRC is one of the most lethal cancers worldwide.[@b1-ott-10-3591] Therapies nowadays can not effectively overwhelm the problems, such as metastasis, recurrence, and chemoresistance.[@b2-ott-10-3591]--[@b4-ott-10-3591] Searching for novel strategies is still of great urgency for CRC treatment. Ixazomib, a second-generation oral proteasome inhibitor, has shown excellent therapeutic effects on multiple myeloma patients. Meanwhile, it also displayed obvious anticancer effects against some solid tumors in vitro and in vivo.[@b17-ott-10-3591]--[@b19-ott-10-3591] Therefore, it is valuable to explore the antitumor effect of ixazomib on CRC.

In the present study, we first investigated the effect of ixazomib on the proliferation of SW620 cells. It was observed that ixazomib had antiproliferation effect on SW620 cells. CCK-8 assay showed that ixazomib significantly reduced cell proliferation in a dose-dependent and time-dependent manner. To further explore the anticancer activities and the potential mechanisms of ixazomib on CRC cells, we performed a combination analysis of microarray and bioinformatics.

According to the microarray analysis, a total of 743 DEGs were identified between ixazomib-treated and untreated samples. Among these, 203 genes, such as *HSPA6*, *CASP7*, and *CDKN1A*, were upregulated and 540 genes, such as *APCDD1*, *MYB*, and *TGFBI*, were downregulated. Up to 83 GO terms were enriched by the DEGs, including BP terms regarding apoptosis, regulation of proliferation, and cell cycle arrest, MF terms regarding protein binding and transcription factor activity, and CC terms regarding mitochondrion and proteasome. There were 37 KEGG pathways significantly affected by ixazomib, such as pathway of apoptosis and pathway of cell cycle. In addition, 46 hub genes including *TP53*, *JUN*, and *ITGA2* and three modules with important functions were mined from the PPI network. These results demonstrated that these altered genes, biological functions, and pathways may be important targets of ixazomib acting against CRC.

HSPA6, heat shock 70 kDa protein 6 (also known as HSP70B′), is a member of heat shock protein 70 (HSP70) family. Although the function of HSPA6 remains far more to be elucidated due to limited researches, a recent study has demonstrated that HSPA6 augmented garlic extract-induced inhibition of proliferation, migration, and invasion of bladder cancer cells.[@b32-ott-10-3591] In that study, HSPA6 was the most highly upregulated gene in bladder cancer EJ cells after garlic extract treatment.[@b32-ott-10-3591] Overexpression of HSPA6 has been verified to enhance the G2/M phase cell cycle arrest and the inhibition of matrix metallopeptidase 9 enzyme activity induced by garlic extract.[@b32-ott-10-3591] In the present study, *HSPA6* was the second most highly upregulated gene as a result of ixazomib treatment (log~2~FC =5.3542, adjusted *P*-value =1.42E−07), suggesting that *HSPA6* may be a key target of ixazomib in preventing tumor proliferation and invasion.

*APCDD1* was the most downregulated gene in response to ixazomib in SW620 cells (log~2~FC =−4.7126, adjusted *P*-value =1.69E−07). *APCDD1* has been proposed to play an important role in the proliferation of cancer cells.[@b33-ott-10-3591] Plasmid-mediated overexpression of *APCDD1* has been shown to promote the growth of colon cancer cells, while reducing the expression of *APCDD1* by transfecting with antisense *S*-oligodeoxynucleotides was declared to decrease tumor growth.[@b33-ott-10-3591] In the study, *APCDD1* was significantly reduced after ixazomib treatment, demonstrating a potential antiproliferation mechanism of ixazomib through downregulating the expression of *APCDD1*.

An important identified anti-CRC effect of ixazomib is the induction of apoptosis, reflecting in the enrichment of apoptotic GO terms such as positive regulation of apoptotic process (GO:0043065), intrinsic apoptotic signaling pathway (GO:0097193), and the activation of apoptosis KEGG pathway, which is the third significant KEGG pathway enriched by the DEGs.

Induction of apoptosis is an important mechanism of anti-cancer agents. There are two mainly independent apoptotic signaling cascades: the extrinsic and intrinsic pathways. The former is usually initiated by the binding of extracellular death receptor ligands, such as tumor necrosis factor (TNF), TNF-related apoptosis-inducing ligand (TRAIL), and Fas ligand (FasL) to their transmenbrane receptors, which results in the activation of caspase-8 and caspase-10. The latter, in contrast, is often triggered by internal sensors, such as DNA damage, metabolic stress, and the presence of unfolded proteins, which leads to the release of mitochondrial cytochrome *c* into the cytosol and the subsequent activation of caspase-9. Caspase-8, caspase-9, and caspase-10 are called initiator caspases. Once activated, they can spark the downstream executor caspases, such as caspase-3, caspase-6, and caspase-7 (CASP7), which cleave a series of substrates, leading to characteristic apoptotic signs including nuclear condensation and DNA fragmentation.[@b34-ott-10-3591]

In the present study, the important executor caspase, *CASP7*, was significantly upregulated in ixazomib-treated samples (log~2~FC =2.1502, adjusted *P*-value =3.05E−07). Meanwhile, apoptotic BPs such as intrinsic apoptotic signaling pathway (GO:0097193) and positive regulation of release of cytochrome *c* from mitochondria (GO:0090200) together with apoptosis-related CCs such as mitochondrion (GO:0005739) and mitochondrial matrix (GO:0005759) were enriched by DEGs, demonstrating that ixazomib may execute its anti-CRC effects by upregulating apoptotic proteins and inducing cytochrome *c* releasing from mitochondria into cytosol, which resulted in the apoptosis of SW620 cells eventually.

Another important anticancer mechanism of ixazomib is the perturbation of cell cycle progression, reflecting in GO cell cycle arrest terms (such as GO:0007050\~cell cycle arrest and GO:0006977\~DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest) and the KEGG cell cycle pathway (hsa04110).

*CDKN1A*, also known as *p21*, was enriched in all the cell cycle-related GO terms and the KEGG cell cycle pathway in the study. The most known function of *p21* is serving as a negative cell cycle regulator. It can block the cell cycle progression through binding to and inhibiting cell cycle promoters such as cyclin-dependent kinases (CDKs) and proliferating cell nuclear antigen (PCNA).[@b35-ott-10-3591] Overexpression of *p21* has been shown to induce G1 phase arrest and inhibit tumor growth in vitro and in vivo.[@b36-ott-10-3591] It is also essential to sustain G2 arrest after DNA damage.[@b37-ott-10-3591]

In the study, *p21* (*CDKN1A*) was significantly upregulated after ixazomib treatment (log~2~FC =2.7978, adjusted *P*-value =1.01E−05), together with cell cycle-related GO terms and cell cycle KEGG pathway, suggesting a possible anticancer mechanism of cell cycle arrest induction by ixazomib on CRC cells.

*Tumor protein p53* (*TP53*), a hub gene with the highest degree in the PPI network (degree =84), was downregulated in response to ixazomib treatment (log~2~FC =−2.0571, adjusted *P*-value =1.96E−06). According to the International Agency for Research on Cancer (IARC) TP53 database (version R18, <http://p53.iarc.fr/>), SW620 is a cell line bearing mutant p53.[@b38-ott-10-3591] Compared to wild-type *p53*, mutations in *TP53* not only result in the loss of tumor suppressive functions but also lead to oncogenic properties, which is called gain oncogenic function (GOF) of the gene.[@b39-ott-10-3591],[@b40-ott-10-3591] The GOF of mutant p53 results in tumor progression and resistance to therapy.[@b40-ott-10-3591] Therefore, targeting mutant *p53* is an attractive strategy of cancer therapy. In the present study, the expression of *TP53* was decreased, indicating that the oncogenic mutation *p53* could be inhibited by ixazomib.

*JUN* (also known as *c-Jun*), is a hub gene with the third highest degree (63) in the PPI network. Despite the oncogenic role of *JUN* reported by some researches,[@b41-ott-10-3591],[@b42-ott-10-3591] recent studies have revealed the tumor suppressive function of the gene.[@b43-ott-10-3591]--[@b45-ott-10-3591] It has been shown that the compound TRX-E-002-1 could induce c-Jun-dependent apoptosis in ovarian cancer stem cells through activating and enhancing the expression of *c-Jun*.[@b43-ott-10-3591] Prolonged activation of *c-Jun* promotes apoptosis induced by α-tocopherol ether-linked acetic acid in human prostate cancer cells.[@b44-ott-10-3591] Moreover, proteasome inhibitors, including bortezomib, carfilzomib, and ixazomib, were demonstrated to trigger multiple myeloma cell death via upregulation of *c-Jun*.[@b45-ott-10-3591]

Consistent with previous researches, *c-Jun* was significantly upregulated in ixazomib-treated samples in the study (log~2~FC =2.5028, adjusted *P*-value =2.05E−06). *c-Jun* was also involved in GO BPs such as response to drug (GO:0042493), release of cytochrome *c* from mitochondria (GO:0001836), and negative regulation of cell proliferation (GO:0008285). Combining these results, ixazomib was indicated to inhibit the proliferation and induce the apoptosis of SW620 cells through upregulating the expression of *c-Jun*.

*ITGA2*, a hub gene in Module 1, has a connectivity degree of 40, which is the fifth highest degree in the PPI network. Integrin α~2~, the protein encoded by *ITGA2*, is an important subunit of integrin α~2~β~1~, which is a receptor for collagens.[@b46-ott-10-3591] Integrin α~2~β~1~ has been demonstrated to suppress metastasis of breast cancer.[@b47-ott-10-3591] Loss of expression of integrin α~2~ subunit resulted in more advanced disease and reduced the survival of CRC patients.[@b48-ott-10-3591] These researches suggested a tumor-suppressing function of *ITGA2*. At present, the expression of *ITGA2* was increased in response to the treatment of ixazomib (log~2~FC =1.5901, adjusted *P*-value =1.48E−04), indicating a potential *ITGA2*-mediated anticancer effect enhanced by ixazomib.

*Activating transcription factor 3* (*ATF3*), a member of the activation transcription factor/cAMP responsive element-binding family of transcription factors, is a hub gene in Module 2 with a degree of 24. ATF3 has significant effects on the cell cycle progression and apoptosis during carcinogenesis.[@b49-ott-10-3591]--[@b52-ott-10-3591] It is reported to induce S phase arrest and apoptosis in diarylheptanoid-induced neuroblastoma cell death.[@b53-ott-10-3591] It also acts as a proapoptotic protein in response to retigeric acid B-induced apoptosis in prostate cancer cells through activating downstream genes involved in cell cycle arrest and cell death, such as *DDIT4*, *GADD45A*, and *CDC25A*.[@b54-ott-10-3591] Moreover, ATF3 plays a driving role in various drugs induced apoptosis in CRC.[@b55-ott-10-3591]--[@b57-ott-10-3591] According to the microarray analysis, *ATF3* was significantly upregulated as a result of ixazomib treatment (log~2~FC =2.0248, adjusted *P*-value =2.32E−05), indicating that ixazomib exerts an antitumor function by elevating the expression of *ATF3*, inducing cell cycle arrest, and apoptosis in CRC.

The functions of Module 3 were mainly related with ubiquitin-dependent protein catabolism and proteasome. The genes of *PSMD1*, *PSMD2*, *PSMC4*, and *PSMD12* in Module 3 encode separate subunits of proteasome (gene database at The National Center for Biotechnology Information (NCBI), <https://www.ncbi.nlm.nih.gov/gene>). They all were found to be upregulated after ixazomib treatment (log~2~FC =1.5276, 2.2345, 2.0028, and 1.7703, respectively, and adjusted *P*-value =1.42E−05, 7.15E−07, 1.30E−06, and 7.24E−06, respectively). Since ixazomib potently inhibits the function of proteasome, upregulation of these genes were considered to be a compensate feedback of CRC cells trying to remedy the decreased performance of proteasome.

Conclusion
==========

Our study provides a comprehensive microarray and bioinformatics analysis of the anticancer effects of ixazomib on CRC. Ixazomib was demonstrated to significantly inhibit the proliferation of SW620 cells in a dose-dependent and time-dependent manner. DEGs, such as *HSPA6*, *APCDD1*, and *p21*, hub genes, including *TP53*, *JUN*, and *ITGA2*, and pathways of apoptosis and cell cycle may be the therapeutic targets of ixazomib against CRC. Our results indicated the promising potential of ixazomib for CRC therapy, and further experimental studies are needed to confirm our findings.

Supplementary materials
=======================

###### 

The rest 32 BP terms in GO functional enrichment analysis

  GO BP term                                                                                       Count   *P*-value
  ------------------------------------------------------------------------------------------------ ------- -----------
  GO:0007165\~signal transduction                                                                  52      0.0223
  GO:0055114\~oxidation-reduction process                                                          30      0.0226
  GO:0009116\~nucleoside metabolic process                                                         4       0.0234
  GO:0001822\~kidney development                                                                   8       0.0234
  GO:0071277\~cellular response to calcium ion                                                     6       0.0259
  GO:0071493\~cellular response to UV-B                                                            3       0.0267
  GO:0030178\~negative regulation of Wnt signaling pathway                                         6       0.0279
  GO:0071356\~cellular response to tumor necrosis factor                                           9       0.0291
  GO:0005975\~carbohydrate metabolic process                                                       12      0.0297
  GO:0043407\~negative regulation of MAP kinase activity                                           5       0.0300
  GO:0071243\~cellular response to arsenic-containing substance                                    3       0.0335
  GO:0010165\~response to X-ray                                                                    4       0.0345
  GO:0000079\~regulation of cyclin-dependent protein serine/threonine kinase activity              5       0.0388
  GO:0006869\~lipid transport                                                                      7       0.0393
  GO:0008285\~negative regulation of cell proliferation                                            21      0.0394
  GO:0071456\~cellular response to hypoxia                                                         8       0.0394
  GO:0003334\~keratinocyte development                                                             3       0.0410
  GO:0070365\~hepatocyte differentiation                                                           3       0.0410
  GO:0006105\~succinate metabolic process                                                          3       0.0410
  GO:0031953\~negative regulation of protein autophosphorylation                                   3       0.0410
  GO:0006983\~ER overload response                                                                 3       0.0410
  GO:0045071\~negative regulation of viral genome replication                                      5       0.0420
  GO:0030819\~positive regulation of cAMP biosynthetic process                                     5       0.0420
  GO:0006974\~cellular response to DNA damage stimulus                                             13      0.0434
  GO:0007050\~cell cycle arrest                                                                    10      0.0441
  GO:0006954\~inflammatory response                                                                20      0.0470
  GO:0030308\~negative regulation of cell growth                                                   9       0.0471
  GO:0043433\~negative regulation of sequence-specific DNA binding transcription factor activity   6       0.0475
  GO:0030433\~ER-associated ubiquitin-dependent protein catabolic process                          6       0.0475
  GO:0016266\~O-glycan processing                                                                  6       0.0475
  GO:0006935\~chemotaxis                                                                           9       0.0490
  GO:0006081\~cellular aldehyde metabolic process                                                  3       0.0491

**Note:** Count refers to the number of DEGs enriched in the GO term.

**Abbreviations:** BP, biological process; DEGs, differentially expressed genes; ER, endoplasmic reticulum; GO, Gene Ontology; MAP, mitogen-activated protein.

###### 

The GO BP functional analysis of Module 1

  GO BP term                                                                                   Count   *P*-value
  -------------------------------------------------------------------------------------------- ------- -----------
  GO:0007565\~female pregnancy                                                                 5       5.01E--06
  GO:0042493\~response to drug                                                                 6       3.85E--05
  GO:0006366\~transcription from RNA polymerase II promoter                                    7       3.88E--05
  GO:0045944\~positive regulation of transcription from RNA polymerase II promoter             8       1.78E--04
  GO:1902895\~positive regulation of pri-miRNA transcription from RNA polymerase II promoter   3       3.07E--04
  GO:0045893\~positive regulation of transcription, DNA-templated                              6       4.55E--04
  GO:0051090\~regulation of sequence-specific DNA binding transcription factor activity        3       4.83E--04
  GO:0043065\~positive regulation of apoptotic process                                         5       5.67E--04
  GO:0032570\~response to progesterone                                                         3       0.0012
  GO:0007568\~aging                                                                            4       0.0013
  GO:0006954\~inflammatory response                                                            5       0.0014
  GO:0008285\~negative regulation of cell proliferation                                        5       0.0016
  GO:0051591\~response to cAMP                                                                 3       0.0016
  GO:0042127\~regulation of cell proliferation                                                 4       0.0017
  GO:0034097\~response to cytokine                                                             3       0.0021
  GO:0061614\~pri-miRNA transcription from RNA polymerase II promoter                          2       0.0026
  GO:0009612\~response to mechanical stimulus                                                  3       0.0027
  GO:0048661\~positive regulation of smooth muscle cell proliferation                          3       0.0028
  GO:0006950\~response to stress                                                               3       0.0029
  GO:0060395\~SMAD protein signal transduction                                                 3       0.0030
  GO:2000144\~positive regulation of DNA-templated transcription, initiation                   2       0.0091
  GO:0009629\~response to gravity                                                              2       0.0104
  GO:0008283\~cell proliferation                                                               4       0.0116
  GO:0000733\~DNA strand renaturation                                                          2       0.0117
  GO:0070365\~hepatocyte differentiation                                                       2       0.0130
  GO:0032496\~response to lipopolysaccharide                                                   3       0.0193
  GO:0035994\~response to muscle stretch                                                       2       0.0208
  GO:0006940\~regulation of smooth muscle contraction                                          2       0.0208
  GO:0044849\~estrous cycle                                                                    2       0.0221
  GO:0030224\~monocyte differentiation                                                         2       0.0221
  GO:0038095\~Fc-epsilon receptor signaling pathway                                            3       0.0225
  GO:0031668\~cellular response to extracellular stimulus                                      2       0.0233
  GO:0051412\~response to corticosterone                                                       2       0.0233
  GO:0001701\~in utero embryonic development                                                   3       0.0246
  GO:0045892\~negative regulation of transcription, DNA-templated                              4       0.0264
  GO:0045987\~positive regulation of smooth muscle contraction                                 2       0.0272
  GO:0007186\~G-protein coupled receptor signaling pathway                                     5       0.0276
  GO:0010165\~response to X-ray                                                                2       0.0284
  GO:0032967\~positive regulation of collagen biosynthetic process                             2       0.0297
  GO:0045648\~positive regulation of erythrocyte differentiation                               2       0.0310
  GO:0042981\~regulation of apoptotic process                                                  3       0.0313
  GO:0021983\~pituitary gland development                                                      2       0.0361
  GO:0006915\~apoptotic process                                                                4       0.0366
  GO:2000379\~positive regulation of reactive oxygen species metabolic process                 2       0.0386
  GO:0046677\~response to antibiotic                                                           2       0.0411
  GO:0070555\~response to interleukin-1                                                        2       0.0424
  GO:0010634\~positive regulation of epithelial cell migration                                 2       0.0424
  GO:0030501\~positive regulation of bone mineralization                                       2       0.0449
  GO:0045786\~negative regulation of cell cycle                                                2       0.0474

**Note:** Count refers to the number of DEGs enriched in the GO BP term.

**Abbreviations:** BP, biological process; DEGs, differentially expressed genes; GO, Gene Ontology.

###### 

The GO BP functional analysis of Module 2

  GO BP term                                                                                                                     Count   *P*-value
  ------------------------------------------------------------------------------------------------------------------------------ ------- -----------
  GO:0036499\~PERK-mediated unfolded protein response                                                                            3       9.81E--06
  GO:1990440\~positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress   3       9.81E--06
  GO:0071850\~mitotic cell cycle arrest                                                                                          3       1.16E--05
  GO:0007050\~cell cycle arrest                                                                                                  3       0.0014
  GO:0036500\~ATF6-mediated unfolded protein response                                                                            2       0.0037
  GO:0006983\~ER overload response                                                                                               2       0.0042
  GO:0043065\~positive regulation of apoptotic process                                                                           3       0.0063
  GO:0034198\~cellular response to amino acid starvation                                                                         2       0.0104
  GO:2000379\~positive regulation of reactive oxygen species metabolic process                                                   2       0.0124
  GO:0071479\~cellular response to ionizing radiation                                                                            2       0.0129
  GO:0043066\~negative regulation of apoptotic process                                                                           3       0.0141
  GO:0034605\~cellular response to heat                                                                                          2       0.0153
  GO:0000079\~regulation of cyclin-dependent protein serine/threonine kinase activity                                            2       0.0161
  GO:0042542\~response to hydrogen peroxide                                                                                      2       0.0211
  GO:0070373\~negative regulation of ERK1 and ERK2 cascade                                                                       2       0.0239
  GO:0043433\~negative regulation of sequence-specific DNA binding transcription factor activity                                 2       0.0247
  GO:0006977\~DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest                      2       0.0256
  GO:0006979\~response to oxidative stress                                                                                       2       0.0450

**Note:** Count refers to the number of DEGs enriched in the GO BP term.

**Abbreviations:** ATF6, activating transcription factor 6; BP, biological process; DEGs, differentially expressed genes; ER, endoplasmic reticulum; ERK1, extracellular signal-regulated kinases 1; ERK2, extracellular signal-regulated kinases 2; GO, Gene Ontology; PERK, protein kinase R-like endoplasmic reticulum kinase.

###### 

The GO BP functional analysis of Module 3

  GO BP term                                                                                                                     Count   *P*-value
  ------------------------------------------------------------------------------------------------------------------------------ ------- -----------
  GO:0090090\~negative regulation of canonical Wnt signaling pathway                                                             5       8.56E--09
  GO:0006521\~regulation of cellular amino acid metabolic process                                                                4       1.05E--07
  GO:0002479\~antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent                    4       2.01E--07
  GO:0038061\~NIK/NF-kappaB signaling                                                                                            4       2.31E--07
  GO:0051436\~negative regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle                            4       2.89E--07
  GO:0051437\~positive regulation of ubiquitin-protein ligase activity involved in regulation of mitotic cell cycle transition   4       3.55E--07
  GO:0031145\~anaphase-promoting complex-dependent catabolic process                                                             4       4.00E--07
  GO:0060071\~Wnt signaling pathway, planar cell polarity pathway                                                                4       6.34E--07
  GO:0043488\~regulation of mRNA stability                                                                                       4       8.93E--07
  GO:0002223\~stimulatory C-type lectin receptor signaling pathway                                                               4       9.46E--07
  GO:0033209\~tumor necrosis factor-mediated signaling pathway                                                                   4       1.35E--06
  GO:0090263\~positive regulation of canonical Wnt signaling pathway                                                             4       1.42E--06
  GO:0050852\~T-cell receptor signaling pathway                                                                                  4       2.67E--06
  GO:0038095\~Fc-epsilon receptor signaling pathway                                                                              4       4.65E--06
  GO:0000209\~protein polyubiquitination                                                                                         4       5.14E--06
  GO:0043161\~proteasome-mediated ubiquitin-dependent protein catabolic process                                                  4       6.90E--06
  GO:0000165\~MAPK cascade                                                                                                       4       1.48E--05

**Note:** Count refers to the number of DEGs enriched in the GO BP term.

**Abbreviations:** BP, biological process; DEGs, differentially expressed genes; GO, Gene Ontology; MAPK, mitogen-activated protein kinase; MHC, major histocompatibility complex; NF-kappaB, nuclear factor-kappaB; NIK, nuclear factor-kappaB-inducing kinase; TAP, transporter associated with antigen processing.
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![The inhibition of ixazomib on the proliferation of SW620 cells.](ott-10-3591Fig1){#f1-ott-10-3591}

![The alterations of gene expression profile.\
**Abbreviation:** log~2~FC, log~2~fold change.](ott-10-3591Fig2){#f2-ott-10-3591}

![Heatmap overview of the hierarchical clustering analysis.](ott-10-3591Fig3){#f3-ott-10-3591}

![The KEGG pathway of apoptosis.\
**Notes:** The red-colored genes are differentially expressed genes enriched in the pathway in the study. Copyright ©2000. Reproduced from KEGG. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. *Nucleic Acids Res*. 2000;28(1):27--30.[@b25-ott-10-3591]\
**Abbreviations:** ADP, adenosine diphosphate; CTLs, cytotoxic T lymphocytes; KEGG, Kyoto Encyclopedia of Genes and Genomes; MOMP, mitochondrial outer membrane permeabilization; NF-κB, nuclear factor-κB; NK, natural killer.](ott-10-3591Fig4){#f4-ott-10-3591}

![Protein--protein interaction network.\
**Notes:** Green nodes stand for downregulated genes, while red nodes stand for upregulated genes. The node size is positively correlated with the degree of the gene. The nodes' colors from green to red reflect the log~2~FC values of the genes from low to high.\
**Abbreviation:** log~2~FC, log~2~fold change.](ott-10-3591Fig5){#f5-ott-10-3591}

![The significant modules in the protein--protein interaction network with MCODE score ≥5 and nodes ≥5.\
**Notes:** (**A**) Module 1 with an MCODE score of 7.565 and the nodes of 24. (**B**) Module 2 with an MCODE score of 5 and the nodes of 9. (**C**) Module 3 with an MCODE score of 5 and the nodes of 5. Green nodes stand for downregulated genes, while red nodes stand for upregulated genes. The node size is positively correlated with the degree of the gene. The nodes' colors from green to red reflect the log~2~FC values of the genes from low to high.\
**Abbreviations:** log~2~FC, log~2~fold change; MCODE, Molecular Complex Detection.](ott-10-3591Fig6){#f6-ott-10-3591}

###### 

The identified top 10 upregulated and downregulated DEGs between ixazomib-treated and untreated samples

  Upregulated DEGs   Downregulated DEGs                                       
  ------------------ -------------------- ----------- ------------- --------- -----------
  *KRT6A*            6.2852               1.12E--07   *APCDD1*      −4.7126   1.69E--07
  *HSPA6*            5.3542               1.42E--07   *KRT40*       −4.6060   4.98E--08
  *GABARAPL1*        4.3530               1.86E--07   *LINC01003*   −4.2484   1.65E--07
  *ADM*              4.2515               4.98E--08   *FAM3B*       −4.2399   1.40E--07
  *NCF2*             4.2303               4.98E--08   *LGR5*        −3.9729   1.40E--07
  *MIR22HG*          4.2234               3.05E--07   *INHBE*       −3.9095   0.000192
  *CD55*             4.1233               4.98E--08   *ASPSCR1*     −3.8382   4.98E--08
  *DUSP5*            4.0788               1.46E--07   *TSTD1*       −3.7015   4.98E--08
  *ZFAND2A*          3.9474               6.17E--08   *FGF3*        −3.6730   1.01E--06
  *CXCL8*            3.8177               5.91E--06   *TFF3*        −3.5758   5.78E--06

**Abbreviations:** DEGs, differentially expressed genes; log~2~FC, log~2~fold change.

###### 

Top 35 predominant BP terms and all the eight CC terms and MF terms in GO functional enrichment analysis

  Category   Term                                                                                                                           Count   *P*-value
  ---------- ------------------------------------------------------------------------------------------------------------------------------ ------- -----------
  GO BP      GO:0006986\~response to unfolded protein                                                                                       9       5.85E--05
             GO:0007568\~aging                                                                                                              16      3.79E--04
             GO:0046677\~response to antibiotic                                                                                             7       5.47E--04
             GO:0042981\~regulation of apoptotic process                                                                                    18      7.22E--04
             GO:0090200\~positive regulation of release of cytochrome c from mitochondria                                                   6       0.0020
             GO:0042149\~cellular response to glucose starvation                                                                            6       0.0024
             GO:0007565\~female pregnancy                                                                                                   10      0.0026
             GO:0042493\~response to drug                                                                                                   21      0.0027
             GO:0090090\~negative regulation of canonical Wnt signaling pathway                                                             14      0.0030
             GO:0048661\~positive regulation of smooth muscle cell proliferation                                                            8       0.0035
             GO:0090084\~negative regulation of inclusion body assembly                                                                     4       0.0036
             GO:0006950\~response to stress                                                                                                 8       0.0038
             GO:0001666\~response to hypoxia                                                                                                14      0.0047
             GO:0042594\~response to starvation                                                                                             6       0.0055
             GO:2000483\~negative regulation of interleukin-8 secretion                                                                     3       0.0062
             GO:0036499\~PERK-mediated unfolded protein response                                                                            4       0.0063
             GO:1990440\~positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress   4       0.0063
             GO:0001836\~release of cytochrome *c* from mitochondria                                                                        5       0.0063
             GO:0051090\~regulation of sequence-specific DNA binding transcription factor activity                                          5       0.0085
             GO:0002009\~morphogenesis of an epithelium                                                                                     4       0.0099
             GO:0019626\~short-chain fatty acid catabolic process                                                                           3       0.0102
             GO:0043065\~positive regulation of apoptotic process                                                                           19      0.0109
             GO:0042026\~protein refolding                                                                                                  4       0.0121
             GO:0006915\~apoptotic process                                                                                                  30      0.0136
             GO:0050679\~positive regulation of epithelial cell proliferation                                                               7       0.0139
             GO:0072655\~establishment of protein localization to mitochondrion                                                             3       0.0149
             GO:0006977\~DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest                      7       0.0162
             GO:0097193\~intrinsic apoptotic signaling pathway                                                                              5       0.0163
             GO:0044344\~cellular response to fibroblast growth factor stimulus                                                             5       0.0163
             GO:0044849\~estrous cycle                                                                                                      4       0.0172
             GO:0032436\~positive regulation of proteasomal ubiquitin-dependent protein catabolic process                                   7       0.0187
             GO:0042127\~regulation of cell proliferation                                                                                   13      0.0199
             GO:0032496\~response to lipopolysaccharide                                                                                     12      0.0202
             GO:0050873\~brown fat cell differentiation                                                                                     5       0.0203
             GO:0009408\~response to heat                                                                                                   6       0.0205
  GO-CC      GO:0005739\~mitochondrion                                                                                                      83      7.17E--08
             GO:0070062\~extracellular exosome                                                                                              143     2.50E--07
             GO:0005759\~mitochondrial matrix                                                                                               31      7.53E--07
             GO:0005615\~extracellular space                                                                                                65      0.0034
             GO:0005777\~peroxisome                                                                                                         10      0.0086
             GO:0000502\~proteasome complex                                                                                                 7       0.0154
             GO:0022624\~proteasome accessory complex                                                                                       4       0.0183
             GO:0005829\~cytosol                                                                                                            130     0.0402
  GO-MF      GO:0005515\~protein binding                                                                                                    339     4.72E--04
             GO:0000982\~transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding           5       0.0070
             GO:0016787\~hydrolase activity                                                                                                 14      0.0138
             GO:0051087\~chaperone binding                                                                                                  8       0.0202
             GO:0008046\~axon guidance receptor activity                                                                                    3       0.0216
             GO:0051082\~unfolded protein binding                                                                                           9       0.0340
             GO:0046703\~natural killer cell lectin-like receptor binding                                                                   3       0.0355
             GO:0016791\~phosphatase activity                                                                                               5       0.0461

**Note:** Count refers to the number of DEGs enriched in the GO term.

**Abbreviations:** BP, biological process; CC, cellular component; DEGs, differentially expressed genes; GO, Gene Ontology; MF, molecular function; PERK, protein kinase R-like endoplasmic reticulum kinase.

###### 

The top 25 significantly enriched KEGG pathways of DEGs

  ID         Term                                          Input number   Corrected *P*-value
  ---------- --------------------------------------------- -------------- ---------------------
  hsa01100   Metabolic pathways                            68             2.07E--12
  hsa00280   Valine, leucine, and isoleucine degradation   11             9.53E--07
  hsa04210   Apoptosis                                     13             0.0003
  hsa00640   Propanoate metabolism                         7              0.0003
  hsa04115   p53 signaling pathway                         9              0.0006
  hsa00561   Glycerolipid metabolism                       8              0.0011
  hsa04010   MAPK signaling pathway                        16             0.0012
  hsa04146   Peroxisome                                    9              0.0012
  hsa05169   Epstein--Barr virus infection                 14             0.0012
  hsa00052   Galactose metabolism                          6              0.0012
  hsa04110   Cell cycle                                    10             0.0038
  hsa00650   Butanoate metabolism                          5              0.0057
  hsa04068   FoxO signaling pathway                        10             0.0057
  hsa04151   PI3K--Akt signaling pathway                   17             0.0057
  hsa01200   Carbon metabolism                             9              0.0061
  hsa04141   Protein processing in endoplasmic reticulum   11             0.0061
  hsa04310   Wnt signaling pathway                         10             0.0071
  hsa00051   Fructose and mannose metabolism               5              0.0080
  hsa04964   Proximal tubule bicarbonate reclamation       4              0.0174
  hsa05132   Salmonella infection                          7              0.0185
  hsa05200   Pathways in cancer                            17             0.0185
  hsa03050   Proteasome                                    5              0.0212
  hsa05205   Proteoglycans in cancer                       11             0.0214
  hsa00010   Glycolysis/gluconeogenesis                    6              0.0214
  hsa00520   Amino sugar and nucleotide sugar metabolism   5              0.0256

**Note:** Input number refers to the number of DEGs enriched in the pathway.

**Abbreviations:** DEGs, differentially expressed genes; KEGG, Kyoto Encyclopedia of Genes and Genomes.

###### 

Hub genes in the PPI network

  Node       Degree   Node        Degree   Node       Degree   Node         Degree
  ---------- -------- ----------- -------- ---------- -------- ------------ --------
  *TP53*     84       *IL8*       22       *TUBB2A*   15       *PSMD1*      12
  *TSPO*     65       *HSPA6*     19       *SGK1*     15       *SYK*        12
  *JUN*      63       *MYB*       19       *DUSP1*    14       *TNFSF10*    11
  *FOS*      49       *CDC25A*    18       *HSPA2*    14       *ETS1*       11
  *ITGA2*    40       *DNAJB1*    17       *DDIT3*    14       *PCCA*       11
  *CDKN1A*   33       *GADD45A*   17       *RASSF1*   14       *CD44*       11
  *DECR1*    31       *PSMD2*     16       *THNSL1*   14       *NMU*        11
  *HSPA5*    30       *HSPH1*     16       *PSMD12*   13       *SERPINH1*   11
  *BMP4*     27       *HADH*      16       *SFN*      13       *CA2*        11
  *HMOX1*    26       *KRT16*     16       *ITPR1*    13       *BBS10*      11
  *ATF3*     24       *FOSL1*     15       *HDAC4*    13                    
  *ISG15*    24       *ANXA1*     15       *BAG3*     13                    

**Abbreviation:** PPI, protein--protein interaction.
